Trials / Unknown
UnknownNCT05633914
Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer
A Phase II Study of Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Hunan Cancer Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is looking to see whether the combination of Tucidinostat and nab-paclitaxel is safe and effective in participants with advanced HR+/HER2- breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tucidinostat | 20mg, po., biw, q3w |
| DRUG | nab-paclitaxel | 125mg/m2, d1, iv.drip, q7d |
Timeline
- Start date
- 2023-02-07
- Primary completion
- 2024-12-01
- Completion
- 2025-12-01
- First posted
- 2022-12-01
- Last updated
- 2023-02-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05633914. Inclusion in this directory is not an endorsement.